Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stergios A Polyzos

Showing results (141-150 of 431) with videos related to

Pageof 44
Sort By:
Bone|August 28, 2019
Off-label uses of denosumab in metabolic bone diseasesStergios A Polyzos, Polyzois Makras, Symeon Tournis, et al.
Hormones (Athens, Greece)|August 29, 2025
Renin-angiotensin-aldosterone system for the management of metabolic dysfunction-associated steatotic liver diseaseStergios A Polyzos, Anastasios Semertzidis, Constantine A Stratakis, et al.
Journal of Clinical Medicine|December 10, 2021
HypophosphatasiaSymeon Tournis, Maria P Yavropoulou, Stergios A Polyzos, et al.
Diabetes & Metabolic Syndrome|September 19, 2020
Nonalcoholic fatty liver disease in males with low testosterone concentrationsStergios A Polyzos, Athanasios Mousiolis, Gesthimani Mintziori, et al.
Metabolism: Clinical and Experimental|September 6, 2016
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonistsStergios A Polyzos, Elisabetta Bugianesi, Jannis Kountouras, et al.
Diabetes, Obesity & Metabolism|June 24, 2025
The effects of anti-obesity medications on bone metabolism: A critical appraisalAthanasios D Anastasilakis, Julien Paccou, Andrea Palermo, et al.
Hormones (Athens, Greece)|March 13, 2024
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver diseaseChara Tsiampali, Ilias D Vachliotis, Antonis Goulas, et al.
Hepatology (Baltimore, Md.)|March 31, 2018
Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?Stergios A Polyzos, Jannis Kountouras, Sotiris Anastasiadis, et al.
Investigative Ophthalmology & Visual Science|January 1, 2016
Helicobacter pylori-Related Impact on Glaucoma PathophysiologyJannis Kountouras, Christos Zavos, Christos Zeglinas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2018
Comment on "Therapeutic Application of an Extract of <i>Helicobacter pylori</i> Ameliorates the Development of Allergic Airway Disease"Jannis Kountouras, Stergios A Polyzos, Michael Doulberis, et al.
Pageof 44

Showing results (141-150 of 431) with videos related to

Sort By:
Pageof 44
Bone|August 28, 2019
Off-label uses of denosumab in metabolic bone diseasesStergios A Polyzos, Polyzois Makras, Symeon Tournis, et al.
Hormones (Athens, Greece)|August 29, 2025
Renin-angiotensin-aldosterone system for the management of metabolic dysfunction-associated steatotic liver diseaseStergios A Polyzos, Anastasios Semertzidis, Constantine A Stratakis, et al.
Journal of Clinical Medicine|December 10, 2021
HypophosphatasiaSymeon Tournis, Maria P Yavropoulou, Stergios A Polyzos, et al.
Diabetes & Metabolic Syndrome|September 19, 2020
Nonalcoholic fatty liver disease in males with low testosterone concentrationsStergios A Polyzos, Athanasios Mousiolis, Gesthimani Mintziori, et al.
Metabolism: Clinical and Experimental|September 6, 2016
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonistsStergios A Polyzos, Elisabetta Bugianesi, Jannis Kountouras, et al.
Diabetes, Obesity & Metabolism|June 24, 2025
The effects of anti-obesity medications on bone metabolism: A critical appraisalAthanasios D Anastasilakis, Julien Paccou, Andrea Palermo, et al.
Hormones (Athens, Greece)|March 13, 2024
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver diseaseChara Tsiampali, Ilias D Vachliotis, Antonis Goulas, et al.
Hepatology (Baltimore, Md.)|March 31, 2018
Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?Stergios A Polyzos, Jannis Kountouras, Sotiris Anastasiadis, et al.
Investigative Ophthalmology & Visual Science|January 1, 2016
Helicobacter pylori-Related Impact on Glaucoma PathophysiologyJannis Kountouras, Christos Zavos, Christos Zeglinas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2018
Comment on "Therapeutic Application of an Extract of <i>Helicobacter pylori</i> Ameliorates the Development of Allergic Airway Disease"Jannis Kountouras, Stergios A Polyzos, Michael Doulberis, et al.
Pageof 44